Expression and ABL collaborate to provide recombinant factor VIII product that is affordable and available to people with hemophilia in the developing world.
Baxter's BAX 855, an experimental extended half-life recombinant factor VIII product, performed well in a Phase 3 clinical trial in patients with severe hemophilia A.
Pfizer’s BeneFIX® shows significantly reduced annual bleeding rates in a clinical trial comparing prophylaxis vs on-demand regimens.
The FDA approved Octapharma's Octagam ® 10% to treat chronic ITP, a platelet disorder.
The FDA approved Novo's NovoSeven RT®, the first recombinant treatment option, for people with Glanzmann's thrombasthenia, a rare clotting disorder.
Bayer HealthCare and Dimension Therapeutics will collaborate on gene therapy for hemophilia A.
The FDA approved Biogen Idec's factor VIII product for people with hemophilia A. It is expected to stretch the intervals between infusions.
Novo Nordisk released new data from its trial of NovoEight, a third-generation, long-acting recombinant factor VIII product.
Biogen and Sobi announced at WFH's World Congress in Australia their intent to produce 1 billion IUs of clotting factor for humanitarian aid programs in the developing world.
Bayer Healthcare announces 2014 recipients of its Bayer Hemophilia Awards Program (BHAP), which supports research and educational initiatives.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car